Clinical Trials Logo

ESWL clinical trials

View clinical trials related to ESWL.

Filter by:
  • None
  • Page 1

NCT ID: NCT05669573 Not yet recruiting - Fasting Clinical Trials

Safety of 6 Hours Feeding After Extracorporeal Shock Wave Lithotripsy of Pancreatic Stone

SHEEL
Start date: May 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety of eating 6 hours after Extracorporeal Shock Wave Lithotripsy (ESWL). At present, ESWL and Endoscopic Retrograde Cholangiopancreatography (ERCP) are the routine ways to treat pancreatic duct stones. For large stones (diameter > 5mm) , ESWL often needs to be performed many times. In clinical practice, fasting for 24 hours after surgery is often used, but long-term fasting brings strong discomfort to patients. However, the consensus for initiation timing of oral nutrition has not yet been established after ESWL. Thus, we design this trial to evaluate the safety of early feeding based on 6 hours parameter instead of the consensus definition.

NCT ID: NCT04619511 Completed - Clinical trials for Chronic Pancreatitis

Risk Factors for Post-ESWL and Post-ERCP Pancreatitis

Start date: October 31, 2016
Phase:
Study type: Observational

The study aimed to identify risk factors for post-ERCP pancreatitis(PEP) after ESWL, and the relationship between the occurrence of post-ESWL pancreatitis and PEP.

NCT ID: NCT03388060 Completed - Urologic Diseases Clinical Trials

(SWL) Versus (ODT) Versus Combined SWL And ODT For Radiolucent Stone

Start date: April 1, 2017
Phase: N/A
Study type: Interventional

compare the efficacy of of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm renal stones.

NCT ID: NCT03385460 Active, not recruiting - Overactive Bladder Clinical Trials

Delivery of Intravesical Botulinum Toxin A Using Low Energy Shock Waves in Treatment of Overactive Bladder: A Feasibility Study

Start date: January 24, 2017
Phase: N/A
Study type: Interventional

We hypothesize that LESWs might temporarily increase urothelial permeability and facilitate delivery of intravesical botulinum toxin without the need for injection.